Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Income towards Parent Company (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Income towards Parent Company for 13 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company fell 278.7% year-over-year to -$3.0 million, compared with a TTM value of -$7.6 million through Dec 2025, down 43.7%, and an annual FY2025 reading of -$8.4 million, down 59.29% over the prior year.
  • Income towards Parent Company was -$3.0 million for Q4 2025 at Abvc Biopharma, down from -$1.3 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$487431.0 in Q3 2024 and bottomed at -$6.9 million in Q4 2021.
  • Average Income towards Parent Company over 5 years is -$2.5 million, with a median of -$2.0 million recorded in 2021.
  • The sharpest move saw Income towards Parent Company plummeted 409.29% in 2022, then surged 87.01% in 2023.
  • Year by year, Income towards Parent Company stood at -$6.9 million in 2021, then skyrocketed by 34.78% to -$4.5 million in 2022, then soared by 87.01% to -$584641.0 in 2023, then crashed by 36.24% to -$796527.0 in 2024, then tumbled by 278.7% to -$3.0 million in 2025.
  • Business Quant data shows Income towards Parent Company for ABVC at -$3.0 million in Q4 2025, -$1.3 million in Q3 2025, and -$2.3 million in Q2 2025.